Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP4A11 | Q02928 | 2/20 | 0.51 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.50 |
| ▸ | MLYCD | O95822 | 2/20 | 0.49 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | HPGD | P15428 | 2/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.44 |
| ▸ | TP53 | P04637 | 1/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.44 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.44 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15329199 | 0.80 | CYP4A11 (0.62) | CYP4A11CYP4F2LOXL2ALDH1A1HPGD | |
| SCHEMBL6961676 | 0.79 | MLYCD (0.47) | MLYCDESRRGMCHR1 | |
| SCHEMBL379954 | 0.79 | CYP4A11 (0.50) | CYP4A11CYP4F2LOXL2ALDH1A1HPGD | |
| SCHEMBL13181406 | 0.79 | MLYCD (0.64) | MLYCDCYP2C19KMT2A | |
| SCHEMBL12329113 | 0.77 | CYP4A11 (0.51) | CYP4A11CYP4F2LOXL2ALDH1A1HPGD | |
| SCHEMBL10426074 | 0.76 | KMT2A (0.60) | ALDH1A1MAPK1KDM4ECYP1A2CYP3A4 | |
| SCHEMBL24835147 | 0.76 | CYP4A11 (0.57) | CYP4A11CYP4F2LOXL2ALDH1A1HPGD | |
| SCHEMBL70185 | 0.76 | CYP4A11 (0.75) | CYP4A11CYP4F2LOXL2ALDH1A1HPGD | |
| SCHEMBL8337316 | 0.75 | CYP4A11 (0.60) | CYP4A11CYP4F2LOXL2ALDH1A1HPGD | |
| SCHEMBL9825792 | 0.75 | CYP4A11 (0.64) | CYP4A11CYP4F2LOXL2ALDH1A1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250195462-A1 | SHORT ACTING PHENYLALKYLAMINE CALCIUM CHANNEL BLOCKERS AND USES THEREOF | MILESTONE PHARMACEUTICALS INC (CA) | 2025-06-19 | — | — | US | disclosed |
| US-20240366552-A1 | SHORT ACTING PHENYLALKYLAMINE CALCIUM CHANNEL BLOCKERS AND USES THEREOF | MILESTONE PHARMACEUTICALS INC (CA) | 2024-11-07 | — | — | US | disclosed |
| US-20240115543-A1 | SHORT ACTING PHENYLALKYLAMINE CALCIUM CHANNEL BLOCKERS AND USES THEREOF | MILESTONE PHARMACEUTICALS INC (CA) | 2024-04-11 | — | — | US | disclosed |
| US-20230255923-A1 | SHORT ACTING PHENYLALKYLAMINE CALCIUM CHANNEL BLOCKERS AND USES THEREOF | MILESTONE PHARMACEUTICALS INC (CA) | 2023-08-17 | — | — | US | disclosed |
| US-20220142963-A1 | SHORT ACTING PHENYLALKYLAMINE CALCIUM CHANNEL BLOCKERS AND USES THEREOF | MILESTONE PHARMACEUTICALS INC (CA) | 2022-05-12 | — | — | US | disclosed |
| US-20210315855-A1 | SHORT ACTING PHENYLALKYLAMINE CALCIUM CHANNEL BLOCKERS AND USES THEREOF | MILESTONE PHARMACEUTICALS INC (CA) | 2021-10-14 | — | — | US | disclosed |
| US-20210059972-A1 | SHORT ACTING PHENYLALKYLAMINE CALCIUM CHANNEL BLOCKERS AND USES THEREOF | MILESTONE PHARMACEUTICALS INC (CA) | 2021-03-04 | — | — | US | disclosed |
| US-20200230097-A1 | SHORT ACTING PHENYLALKYLAMINE CALCIUM CHANNEL BLOCKERS AND USES THEREOF | MILESTONE PHARMACEUTICALS INC (CA) | 2020-07-23 | — | — | US | disclosed |
| US-20190142781-A1 | SHORT ACTING PHENYLALKYLAMINE CALCIUM CHANNEL BLOCKERS AND USES THEREOF | MILESTONE PHARMACEUTICALS INC (CA) | 2019-05-16 | — | — | US | disclosed |
| US-20180280339-A1 | SHORT ACTING PHENYLALKYLAMINE CALCIUM CHANNEL BLOCKERS AND USES THEREOF | MILESTONE PHARMACEUTICALS INC (CA) | 2018-10-04 | — | — | US | disclosed |
| US-9737503-B2 | Short acting phenylalkylamine calcium channel blockers and uses thereof | MILESTONE PHARMACEUTICALS INC. (CA) | 2017-08-22 | — | — | US | disclosed |
| US-20160374982-A1 | SHORT ACTING PHENYLALKYLAMINE CALCIUM CHANNEL BLOCKERS AND USES THEREOF | ACQUIOM AGENCY SERVICES, LLC | 2016-12-29 | — | — | US | disclosed |
| US-9463179-B2 | Short acting phenylalkylamine calcium channel blockers and uses thereof | MILESTONE PHARMACEUTICALS INC. (CA) | 2016-10-11 | — | — | US | disclosed |
| US-20160074354-A1 | SHORT ACTING PHENYLALKYLAMINE CALCIUM CHANNEL BLOCKERS AND USES THEREOF | ACQUIOM AGENCY SERVICES, LLC | 2016-03-17 | — | — | US | disclosed |
| US-9227918-B2 | Short acting phenylalkylamine calcium channel blockers and uses thereof | MILESTONE PHARMACEUTICALS (CA) | 2016-01-05 | — | — | US | disclosed |
| US-20140296335-A1 | SHORT ACTING PHENYLALKYLAMINE CALCIUM CHANNEL BLOCKERS AND USES THEREOF | ACQUIOM AGENCY SERVICES, LLC | 2014-10-02 | — | — | US | disclosed |
| EP-2170050-B1 | Short acting phenylalkylamine calcium channel blockers and uses thereof | MILESTONE PHARMACEUTICALS INC (CA) | 2014-06-18 | — | — | EP | disclosed |
| US-20100190852-A1 | SHORT ACTING PHENYLALKYLAMINE CALCIUM CHANNEL BLOCKERS AND USES THEREOF | MILESTONE PHARMACEUTICALS INC. (CA) | 2010-07-29 | — | — | US | disclosed |
| EP-2170050-A1 | SHORT ACTING PHENYLALKYLAMINE CALCIUM CHANNEL BLOCKERS AND USES THEREOF | Milestone Pharmaceuticals Inc. (CA) | 2010-04-07 | — | — | EP | disclosed |
| WO-2008156820-A1 | SHORT ACTING PHENYLALKYLAMINE CALCIUM CHANNEL BLOCKERS AND USES THEREOF | MILESTONE PHARMACEUTICALS INC. (CA) | 2008-12-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (14 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200230097-A1 | SHORT ACTING PHENYLALKYLAMINE CALCIUM CHANNEL BLOCKERS AND USES THEREOF | ORAI1, ATP2A1, RYR2 | CYP4A11 2712/4885CYP4F2 3383/4885MLYCD 3513/4885 |
| US-20240115543-A1 | SHORT ACTING PHENYLALKYLAMINE CALCIUM CHANNEL BLOCKERS AND USES THEREOF | ORAI1, ATP2A1, RYR2 | CYP4A11 2712/4885CYP4F2 3383/4885MLYCD 3513/4885 |
| US-20220142963-A1 | SHORT ACTING PHENYLALKYLAMINE CALCIUM CHANNEL BLOCKERS AND USES THEREOF | ORAI1, ATP2A1, RYR2 | CYP4A11 2712/4885CYP4F2 3383/4885MLYCD 3513/4885 |
| US-20190142781-A1 | SHORT ACTING PHENYLALKYLAMINE CALCIUM CHANNEL BLOCKERS AND USES THEREOF | ORAI1, ATP2A1, RYR2 | CYP4A11 2712/4885CYP4F2 3383/4885MLYCD 3513/4885 |
| US-20230255923-A1 | SHORT ACTING PHENYLALKYLAMINE CALCIUM CHANNEL BLOCKERS AND USES THEREOF | ORAI1, ATP2A1, RYR2 | CYP4A11 2712/4885CYP4F2 3383/4885MLYCD 3513/4885 |
| US-20160374982-A1 | SHORT ACTING PHENYLALKYLAMINE CALCIUM CHANNEL BLOCKERS AND USES THEREOF | ORAI1, ATP2A1, RYR2 | CYP4A11 2712/4885CYP4F2 3383/4885MLYCD 3513/4885 |
| US-20240366552-A1 | SHORT ACTING PHENYLALKYLAMINE CALCIUM CHANNEL BLOCKERS AND USES THEREOF | ORAI1, ATP2A1, RYR2 | CYP4A11 2712/4885CYP4F2 3383/4885MLYCD 3513/4885 |
| US-20210315855-A1 | SHORT ACTING PHENYLALKYLAMINE CALCIUM CHANNEL BLOCKERS AND USES THEREOF | ORAI1, ATP2A1, RYR2 | CYP4A11 2712/4885CYP4F2 3383/4885MLYCD 3513/4885 |
| US-20210059972-A1 | SHORT ACTING PHENYLALKYLAMINE CALCIUM CHANNEL BLOCKERS AND USES THEREOF | ORAI1, ATP2A1, RYR2 | CYP4A11 2712/4885CYP4F2 3383/4885MLYCD 3513/4885 |
| US-20140296335-A1 | SHORT ACTING PHENYLALKYLAMINE CALCIUM CHANNEL BLOCKERS AND USES THEREOF | ORAI1, ATP2A1, RYR2 | CYP4A11 2712/4885CYP4F2 3383/4885MLYCD 3513/4885 |
| US-20180280339-A1 | SHORT ACTING PHENYLALKYLAMINE CALCIUM CHANNEL BLOCKERS AND USES THEREOF | ORAI1, ATP2A1, RYR2 | CYP4A11 2712/4885CYP4F2 3383/4885MLYCD 3513/4885 |
| US-20160074354-A1 | SHORT ACTING PHENYLALKYLAMINE CALCIUM CHANNEL BLOCKERS AND USES THEREOF | ORAI1, ATP2A1, RYR2 | CYP4A11 2712/4885CYP4F2 3383/4885MLYCD 3513/4885 |
| US-20100190852-A1 | SHORT ACTING PHENYLALKYLAMINE CALCIUM CHANNEL BLOCKERS AND USES THEREOF | ORAI1, ATP2A1, RYR2 | CYP4A11 2712/4885CYP4F2 3383/4885MLYCD 3513/4885 |
| US-20250195462-A1 | SHORT ACTING PHENYLALKYLAMINE CALCIUM CHANNEL BLOCKERS AND USES THEREOF | ORAI1, ATP2A1, RYR2 | CYP4A11 2712/4885CYP4F2 3383/4885MLYCD 3513/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.